Quick Answer
Adagio Medical Holdings, Inc. reported R&D Expense of $10.64 million for fiscal year 2025.
Adagio Medical Holdings, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.64M | -30.9% |
| 2023 | $15.40M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.77M | +127.9% | +40.7% |
| June 30, 2025 | $1.97M | -31.2% | -46.1% |
| March 31, 2025 | $3.66M | +5.5% | +200.7% |
| September 30, 2024 | $1.22M | -72.5% | -2.7% |
| July 31, 2024 | $1.25M | — | -56.3% |
| June 30, 2024 | $2.87M | — | -17.4% |
| March 31, 2024 | $3.47M | — | -21.5% |
| September 30, 2023 | $4.42M | — | — |
- Adagio Medical Holdings, Inc. showed a decrease of -30.9% in R&D Expense compared to the prior fiscal year.
- Over the 2023–2025 period, Adagio Medical Holdings, Inc.’s r&d expense has declined by 30.9% (from $15.40 million to $10.64 million).
- The most recent figure is from Adagio Medical Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: